



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/52, A61K 38/19, C12N 15/19, 5/10, C07K 14/47, A61K 38/17</p>	<p>A2</p>	<p>(11) International Publication Number: WO 97/40151</p> <p>(43) International Publication Date: 30 October 1997 (30.10.97)</p>
<p>(21) International Application Number: PCT/US97/06125</p> <p>(22) International Filing Date: 14 April 1997 (14.04.97)</p> <p>(30) Priority Data: 08/635,311 19 April 1996 (19.04.96) US 08/781,226 10 January 1997 (10.01.97) US</p> <p>(71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US).</p> <p>(72) Inventors: JACOBS, Kenneth; 151 Beaumont Avenue, Newton, MA 02160 (US). MCCOY, John, M.; 56 Howard Street, Reading, MA 01867 (US). RACIE, Lisa, A.; 124 School Street, Acton, MA 01720 (US). LAVALLIE, Edward, R.; 90 Green Meadow Drive, Tewksbury, MA 01876 (US). MERBERG, David; 2 Orchard Drive, Acton, MA 01720 (US). SPAULDING, Vikki; 11 Meadowbank Road, Billerica, MA 01821 (US).</p> <p>(74) Agent: BROWN, Scott, A.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).</p>		<p>(81) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM</p> <p>(57) Abstract</p> <p>The invention provides 5 clones G52-24, H1075-1, J59-41, H83-22, J143-1 isolated from a human PBMC cDNA library and one clone M97-2 from a human glioblastoma cell line T98G cDNA library using a method of screening for cDNAs encoding secreted proteins. Determination of the nucleotide sequences and of the deduced amino acid sequences.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

5 This application is a continuation-in-part of application Ser. No. 08/635,311, filed April 19, 1996.

FIELD OF THE INVENTION

10 The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

BACKGROUND OF THE INVENTION

15 Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed.

20

25

SUMMARY OF THE INVENTION

30 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:2;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:2 from nucleotide 1 to nucleotide 1014;

35

(c) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone G52_24 deposited under accession number ATCC 98028;

5 (d) a polynucleotide encoding the full length protein encoded by the cDNA insert of clone G52_24 deposited under accession number ATCC 98028;

(e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone G52_24 deposited under accession number ATCC 98028;

10 (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone G52_24 deposited under accession number ATCC 98028;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:3;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:3 having biological activity;

15 (i) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:26 from nucleotide 732 to nucleotide 1274;

(j) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:27;

20 (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(d) or (i) above;

(l) a polynucleotide which encodes a species homologue of the protein of (g), (h) or (j) above; and

(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

25 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:2 from nucleotide 1 to nucleotide 1014; the nucleotide sequence of the full length protein coding sequence of clone G52_24 deposited under accession number ATCC 98028; or the nucleotide sequence of the mature protein coding sequence of clone G52_24 deposited under accession number ATCC 98028. In other preferred embodiments, the polynucleotide
30 encodes the full length or mature protein encoded by the cDNA insert of clone G52_24 deposited under accession number ATCC 98028. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:3 from amino acid 201 to amino acid 221.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:2, SEQ ID NO:1 or SEQ ID NO:4 .

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:3;
- (b) the amino acid sequence of SEQ ID NO:3 from amino acid 201 to amino acid 221;
- (c) fragments of the amino acid sequence of SEQ ID NO:3; and
- (d) the amino acid sequence encoded by the cDNA insert of clone G52_24 deposited under accession number ATCC98028;
- (e) the amino acid sequence of SEQ ID NO:27;
- (f) the amino acid sequence of SEQ ID NO:27 beginning with amino acid 41;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:3 or the amino acid sequence of SEQ ID NO:3 from amino acid 201 to amino acid 221.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 181 to nucleotide 325;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 274 to nucleotide 325;
- (d) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone M97_2 deposited under accession number ATCC 98028;
- (e) a polynucleotide encoding the full length protein encoded by the cDNA insert of clone M97_2 deposited under accession number ATCC 98028;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone M97_2 deposited under accession number ATCC 98028;

(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone M97_2 deposited under accession number ATCC 98028;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;

5 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity;

(j) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:28 from nucleotide 171 to nucleotide 587;

10 (k) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:29;

(l) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) or (j) above; and

(m) a polynucleotide which encodes a species homologue of the protein of (h), (i) or (k) above .

15 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 181 to nucleotide 325; the nucleotide sequence of SEQ ID NO:5 from nucleotide 274 to nucleotide 325; the nucleotide sequence of the full length protein coding sequence of clone M97_2 deposited under accession number ATCC 98028; or the nucleotide sequence of the mature protein coding sequence of clone M97_2 deposited under
20 accession number ATCC 98028. In other preferred embodiments, the polynucleotide encodes the full length or mature protein encoded by the cDNA insert of clone M97_2 deposited under accession number ATCC 98028. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 48.

25 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:5, SEQ ID NO:7 or SEQ ID NO:28.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 30 (a) the amino acid sequence of SEQ ID NO:6;
- (b) the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 48;
- (c) fragments of the amino acid sequence of SEQ ID NO:6; and

(d) the amino acid sequence encoded by the cDNA insert of clone M97_2 deposited under accession number ATCC98028;

(e) the amino acid sequence of SEQ ID NO:29;
the protein being substantially free from other mammalian proteins. Preferably such protein
5 comprises the amino acid sequence of SEQ ID NO:6 or the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 48.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
10 NO:8;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 36 to nucleotide 522;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 93 to nucleotide 522;

(d) a polynucleotide comprising the nucleotide sequence of the full
15 length protein coding sequence of clone H1075_1 deposited under accession number ATCC 98028;

(e) a polynucleotide encoding the full length protein encoded by the cDNA insert of clone H1075_1 deposited under accession number ATCC 98028;

(f) a polynucleotide comprising the nucleotide sequence of the mature
20 protein coding sequence of clone H1075_1 deposited under accession number ATCC 98028;

(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone H1075_1 deposited under accession number ATCC 98028;

(h) a polynucleotide encoding a protein comprising the amino acid
25 sequence of SEQ ID NO:9;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:9 having biological activity;

(j) a polynucleotide comprising the nucleotide sequence of SEQ ID
30 NO:30 from nucleotide 19 to nucleotide 471;

(k) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:31;

(l) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) or (j) above; and

(m) a polynucleotide which encodes a species homologue of the protein of (h), (i) or (k) above.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:8 from nucleotide 36 to nucleotide 522; the nucleotide sequence of SEQ ID NO:8 from
5 nucleotide 93 to nucleotide 522; the nucleotide sequence of the full length protein coding sequence of clone H1075_1 deposited under accession number ATCC 98028; or the nucleotide sequence of the mature protein coding sequence of clone H1075_1 deposited under accession number ATCC 98028. In other preferred embodiments, the polynucleotide encodes the full length or mature protein encoded by the cDNA insert of clone H1075_1
10 deposited under accession number ATCC 98028. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:9 from amino acid 1 to amino acid 101.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:8, SEQ ID NO:10 or SEQ ID NO:30.

15 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:9;
- (b) the amino acid sequence of SEQ ID NO:9 from amino acid 1 to
20 amino acid 101;
- (c) fragments of the amino acid sequence of SEQ ID NO:9;
- (d) the amino acid sequence encoded by the cDNA insert of clone H1075_1 deposited under accession number ATCC98028;
- (e) the amino acid sequence of SEQ ID NO:31; and
- 25 (f) the amino acid sequence of SEQ ID NO:31 beginning with amino acid 20;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:9 or the amino acid sequence of SEQ ID NO:9 from amino acid 1 to amino acid 101.

30 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 88 to nucleotide 499;
- (c) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone J59_41 deposited under accession number ATCC 98028;
- 5 (d) a polynucleotide encoding the full length protein encoded by the cDNA insert of clone J59_41 deposited under accession number ATCC 98028;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone J59_41 deposited under accession number ATCC 98028;
- 10 (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone J59_41 deposited under accession number ATCC 98028;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
- 15 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity;
- (i) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 62 to nucleotide 1069;
- (j) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:33 beginning with amino acid 185;
- 20 (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) or (i) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (g), (h) or (j) above; and
- 25 (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:11 from nucleotide 88 to nucleotide 499; the nucleotide sequence of the full length protein coding sequence of clone J59_41 deposited under accession number ATCC 98028;

30 or the nucleotide sequence of the mature protein coding sequence of clone J59_41 deposited under accession number ATCC 98028. In other preferred embodiments, the polynucleotide encodes the full length or mature protein encoded by the cDNA insert of clone J59_41 deposited under accession number ATCC 98028. In yet other preferred embodiments, the

present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12 from amino acid 45 to amino acid 113.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:11 or SEQ ID NO:13 or SEQ ID NO:32.

5 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
- (b) the amino acid sequence of SEQ ID NO:12 from amino acid 45 to
10 amino acid 113;
- (c) fragments of the amino acid sequence of SEQ ID NO:12;
- (d) the amino acid sequence encoded by the cDNA insert of clone J59_41 deposited under accession number ATCC98028;
- (e) the amino acid sequence of SEQ ID NO:33;
- 15 (f) the amino acid sequence of SEQ ID NO:33 beginning with amino acid 185;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:12 or the amino acid sequence of SEQ ID NO:12 from amino acid 45 to amino acid 113.

20 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:14;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
25 NO:14 from nucleotide 138 to nucleotide 479;
- (c) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone H83_22 deposited under accession number ATCC 98028;
- (d) a polynucleotide encoding the full length protein encoded by the
30 cDNA insert of clone H83_22 deposited under accession number ATCC 98028;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone H83_22 deposited under accession number ATCC 98028;

(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone H83_22 deposited under accession number ATCC 98028;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:15;

5 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:15 having biological activity;

(i) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:34 from nucleotide 56 to nucleotide 847;

10 (j) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:35;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) or (i) above;

(l) a polynucleotide which encodes a species homologue of the protein of (g), (h) or (j) above ; and

15 (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:14 from nucleotide 138 to nucleotide 479; the nucleotide sequence of the full length protein coding sequence of clone H83_22 deposited under accession number ATCC 98028; 20 or the nucleotide sequence of the mature protein coding sequence of clone H83_22 deposited under accession number ATCC 98028. In other preferred embodiments, the polynucleotide encodes the full length or mature protein encoded by the cDNA insert of clone H83_22 deposited under accession number ATCC 98028.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ 25 ID NO:14 or SEQ ID NO:16 or SEQ ID NO:34.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 30 (a) the amino acid sequence of SEQ ID NO:15;
- (b) fragments of the amino acid sequence of SEQ ID NO:15;
- (c) the amino acid sequence encoded by the cDNA insert of clone H83_22 deposited under accession number ATCC98028; and
- (d) the amino acid sequence of SEQ ID NO:35;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:15.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 149 to nucleotide 461;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
10 NO:17 from nucleotide 212 to nucleotide 461;
- (d) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone J143_1 deposited under accession number ATCC 98028;
- (e) a polynucleotide encoding the full length protein encoded by the
15 cDNA insert of clone J143_1 deposited under accession number ATCC 98028;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone J143_1 deposited under accession number ATCC 98028;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA
20 insert of clone J143_1 deposited under accession number ATCC 98028;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity;
- 25 (j) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:36 from nucleotide 158 to nucleotide 910;
- (k) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:37;
- (l) a polynucleotide which is an allelic variant of a polynucleotide of
30 (a)-(g) or (j) above; and
- (m) a polynucleotide which encodes a species homologue of the protein of (h), (i) or (k) above.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:17 from nucleotide 149 to nucleotide 461; the nucleotide sequence of SEQ ID NO:17

from nucleotide 212 to nucleotide 461; the nucleotide sequence of the full length protein coding sequence of clone J143_1 deposited under accession number ATCC 98028; or the nucleotide sequence of the mature protein coding sequence of clone J143_1 deposited under accession number ATCC 98028. In other preferred embodiments, the polynucleotide
5 encodes the full length or mature protein encoded by the cDNA insert of clone J143_1 deposited under accession number ATCC 98028.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:17 or SEQ ID NO:19 or SEQ ID NO:36.

In other embodiments, the present invention provides a composition comprising a
10 protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:18;
- (b) fragments of the amino acid sequence of SEQ ID NO:18;
- (c) the amino acid sequence encoded by the cDNA insert of clone
15 J143_1 deposited under accession number ATCC98028;
- (d) the amino acid sequence of SEQ ID NO:36; and
- (e) the amino acid sequence of SEQ ID NO:36 beginning with amino acid 22;

the protein being substantially free from other mammalian proteins. Preferably such protein
20 comprises the amino acid sequence of SEQ ID NO:18.

In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions.

Processes are also provided for producing a protein, which comprise:

- 25 (a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and
- (b) purifying the protein from the culture.

The protein produced according to such methods is also provided by the present invention. Preferred embodiments include those in which the protein produced by such process is a
30 mature form of the protein.

Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.

Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

5

BRIEF DESCRIPTION OF FIGURES

Fig. 1 is an autoradiograph evidencing the expression of the following clone(s) disclosed herein: G52_24.

Fig. 2 is an autoradiograph evidencing the expression of the following clone(s) disclosed herein: H83_22.

10

DETAILED DESCRIPTION

ISOLATED PROTEINS AND POLYNUCLEOTIDES

Nucleotide and amino acid sequences are reported below for each clone and protein disclosed in the present application. In some instances the sequences are preliminary and may include some incorrect or ambiguous bases or amino acids. The actual nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full length and mature) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence.

For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing. Because of the partial ambiguity in reported sequence information, reported protein sequences include "Xaa" designators. These "Xaa" designators indicate either (1) a residue which cannot be identified because of nucleotide sequence ambiguity or (2) a stop codon in the determined nucleotide sequence where applicants believe one should not exist (if the nucleotide sequence were determined definitively).

As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

30

Clone "G52_24"

A polynucleotide of the present invention has been identified as clone "G52_24". G52_24 was isolated from a human PBMC cDNA library using methods which are selective for cDNAs encoding secreted proteins. G52_24 is a full-length clone, including the entire
5 coding sequence of a secreted protein (also referred to herein as "G52_24 protein").

The nucleotide sequence of the 5' portion of G52_24 as presently determined is reported in SEQ ID NO:1. An additional internal nucleotide sequence from G52_24 as presently determined is reported in SEQ ID NO:2. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence
10 is reported in SEQ ID NO:3. Additional nucleotide sequence from the 3' portion of G52_24, including the polyA tail, is reported in SEQ ID NO:4.

The nucleotide sequence disclosed herein for G52_24 was searched against the GenBank database using BLASTA/BLASTX and FASTA search protocols. G52_24 demonstrated at least some homology with the early activation cell surface antigen CD69
15 (GenPept accession number Z22576). The search also found hits at GenBank accession numbers R12300 and X87344. Based upon homology, G52_24 proteins and each homologous protein or peptide may share at least some activity.

Additional full-length nucleotide and amino acid sequence for G52_24 are provided in SEQ ID NO:26 and SEQ ID NO:27, respectively. Based on this sequence information
20 applicants predict that the mature amino acid sequence for G52_24 begins with amino acid 41 of SEQ ID NO:27.

Clone "M97_2"

A polynucleotide of the present invention has been identified as clone "M97_2". M97_2 was isolated from a human neural tissue (glioblastoma cell line T98G) cDNA library
25 using methods which are selective for cDNAs encoding secreted proteins. M97_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "M97_2 protein").

The nucleotide sequence of the 5' portion of M97_2 as presently determined is reported in SEQ ID NO:5. What applicants presently believe is the proper reading frame for
30 the coding region is indicated in SEQ ID NO:6. The predicted acid sequence of the M97_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6.

Amino acids 1 to 31 are the predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 32. Additional nucleotide sequence from the 3' portion of M97_2, including the polyA tail, is reported in SEQ ID NO:7.

The nucleotide sequence disclosed herein for M97_2 was searched against the GenBank database using BLASTA/BLASTX and FASTA search protocols. M97_2 demonstrated at least some identity with an EST identified as "H. sapiens partial cDNA sequence; clone C6F07" (GenBank accession number Z25379). Based upon identity, M97_2 proteins and each identical protein or peptide may share at least some activity.

Additional full-length nucleotide and amino acid sequence for M97_2 are provided in SEQ ID NO:28 and SEQ ID NO:29, respectively.

Clone "H1075_1"

A polynucleotide of the present invention has been identified as clone "H1075_1". H1075_1 was isolated from a human PBMC cDNA library using methods which are selective for cDNAs encoding secreted proteins. H1075_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "H1075_1 protein").

The nucleotide sequence of the 5' portion of H1075_1 as presently determined is reported in SEQ ID NO:8. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:9. The predicted acid sequence of the H1075_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:9. Amino acids 1 to 19 are the predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Additional nucleotide sequence from the 3' portion of H1075_1, including the polyA tail, is reported in SEQ ID NO:10.

The nucleotide sequence disclosed herein for H1075_1 was searched against the GenBank database using BLASTA/BLASTX and FASTA search protocols. H1075_1 demonstrated at least some identity with the sequence of a tissue specific secretory protein identified at GenBank accession number X67698 (GenPept A18921). Based upon identity, H1075_1 proteins and each identical protein or peptide may share at least some activity.

Additional full-length nucleotide and amino acid sequence for H1075_1 are provided in SEQ ID NO:30 and SEQ ID NO:31, respectively. Based on this sequence information applicants predict that the mature amino acid sequence for H1075_1 begins with amino acid 20 of SEQ ID NO:31.

Clone "J59_41"

A polynucleotide of the present invention has been identified as clone "J59_41". J59_41 was isolated from a human PBMC cDNA library using methods which are selective for cDNAs encoding secreted proteins. J59_41 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "J59_41 protein").

The nucleotide sequence of the 5' portion of J59_41 as presently determined is reported in SEQ ID NO:11. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:12. The predicted acid sequence of the J59_41 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12. Additional nucleotide sequence from the 3' portion of J59_41, including the polyA tail, is reported in SEQ ID NO:13.

The nucleotide sequence disclosed herein for J59_41 was searched against the GenBank database using BLASTA/BLASTX and FASTA search protocols. J59_41 demonstrated at least some homology with the cosmid F54E7.1 gene product (caenorhabditis elegans). The search found a hit at GenBank accession number R21739. Based upon homology, J59_41 proteins and each homologous protein or peptide may share at least some activity.

Additional full-length nucleotide and amino acid sequence for J59_41 are provided in SEQ ID NO:32 and SEQ ID NO:33, respectively. Based on this sequence information applicants predict that the mature amino acid sequence for J59_41 begins with amino acid 185 of SEQ ID NO:33.

Clone "H83_22"

A polynucleotide of the present invention has been identified as clone "H83_22". H83_22 was isolated from a human PBMC cDNA library using methods which are selective for cDNAs encoding secreted proteins. H83_22 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "H83_22 protein").

The nucleotide sequence of the 5' portion of H83_22 as presently determined is reported in SEQ ID NO:14. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:15. The predicted acid sequence of the H83_22 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:15. Additional nucleotide sequence from the 3' portion of H83_22, including the polyA tail, is reported in SEQ ID NO:16.

The nucleotide sequence disclosed herein for H83_22 was searched against the GenBank database using BLASTA/BLASTX and FASTA search protocols. No hits were found in the database. The amino acid sequence of H83_22 indicates that it may be a novel serine protease.

Additional full-length nucleotide and amino acid sequence for H83_22 are provided in SEQ ID NO:34 and SEQ ID NO:35, respectively.

Clone "J143_1"

A polynucleotide of the present invention has been identified as clone "J143_1". J143_1 was isolated from a human PBMC cDNA library using methods which are selective for cDNAs encoding secreted proteins. J143_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "J143_1 protein").

5 The nucleotide sequence of the 5' portion of J143_1 as presently determined is reported in SEQ ID NO:17. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:18. The predicted acid sequence of the J143_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:18. Amino acids 1 to 21 are the predicted leader/signal sequence, with the predicted
10 mature amino acid sequence beginning at amino acid 22. Additional nucleotide sequence from the 3' portion of J143_1, including the polyA tail, is reported in SEQ ID NO:19.

The nucleotide sequence disclosed herein for J143_1 was searched against the GenBank database using BLASTA/BLASTX and FASTA search protocols. The clone showed at least some identity with an EST identified as "yh04a07.r1 H. sapiens cDNA
15 clone 41951 5'".

Additional full-length nucleotide and amino acid sequence for J143_1 are provided in SEQ ID NO:36 and SEQ ID NO:37, respectively. Based on this sequence information applicants predict that the mature amino acid sequence for J143_1 begins with amino acid
20 22 of SEQ ID NO:37.

Figs. 1 and 2 are autoradiographs evidencing expression of clones of the present invention. All clones were expressed in COS cells.

Deposit of Clones

25 Clones G52_24, M97_2, H1075_1, J59_41, H83_22 and J143_1 were deposited on April 19, 1996 with the American Type Culture Collection under accession number ATCC 98028, from which each clone comprising a particular polynucleotide is obtainable. Each clone has been transfected into separate bacterial cells (*E. coli*) in this composite deposit. Bacterial cells containing a particular clone can be obtained from the composite
30 deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of the oligonucleotide

probe that was used to isolate each full-length clone is identified below, and should be most reliable in isolating the clone of interest.

	<u>Clone</u>	<u>Probe Sequence</u>
5	G52_24	SEQ ID NO:20
	M97_2	SEQ ID NO:21
	H1075_1	SEQ ID NO:22
	J59_41	SEQ ID NO:23
	H83_22	SEQ ID NO:24
10	J143_1	SEQ ID NO:25

The design of the oligonucleotide probe should preferably follow these parameters:

- (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;
- (b) It should be designed to have a T_m of approx. 80 ° C (assuming 2° for each A or T and 4 degrees for each G or C).

The oligonucleotide should preferably be labeled with γ -³²P ATP (specific activity 6000 Ci/mmmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmmole.

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 μ l of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 μ g/ml. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 μ g/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 µg/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to 1e+6 dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, *et al.*, Bio/Technology 10, 773-778 (1992) and in R.S. McDowell, *et al.*, J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form

of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell. The sequence of the mature form of the protein may also be determinable from the amino acid sequence of the full-length form.

5 The present invention also provides genes corresponding to the cDNA sequences disclosed herein. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic
10 materials.

 Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and
15 transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information.

 Species homologs of the disclosed polynucleotides and proteins are also provided by the present invention. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable
20 nucleic acid source from the desired species.

 The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous or related to that encoded by the polynucleotides .

25 The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R.
30 Kaufman, Methods in Enzymology 185, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell
5 strains derived from *in vitro* culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*,
10 or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional
15 protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell
20 expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

25 The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column
30 containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, MA), Pharmacia (Piscataway, NJ) and InVitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from Kodak (New Haven, CT).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid

to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

5 Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

10

USES AND BIOLOGICAL ACTIVITY

The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention
15 may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

Research Uses and Utilities

20 The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight
25 markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of
30 discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a

receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

- 5 The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein
- 10 is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction.
- 15 Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

- 20 Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

25 Nutritional Uses

- Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to
- 30 the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon γ , Schreiber, R.D. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In

Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., *Proc. Natl. Acad. Sci. U.S.A.* 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., *Proc. Natl. Acad. Sci. USA* 77:6091-6095, 1980; Weinberger et al., *Eur. J. Immun.* 11:405-411, 1981; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Takai et al., *J. Immunol.* 140:508-512, 1988.

Immune Stimulating or Suppressing Activity

A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, *Leishmania* spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus

erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), *e.g.*, preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (*e.g.*, B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this manner prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby

inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

5 The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described
10 in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc. Natl. Acad. Sci. USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.

15 Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents
20 which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents
25 in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosus in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental
30 Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune

response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

5 Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses
10 would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

15 In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (*e.g.*, sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired,
20 the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the
25 transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor
30 cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (*e.g.*, a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β_2 microglobulin protein or an MHC class II α chain protein and an MHC class II β chain protein to thereby express MHC

class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, *Immunologic studies in Humans*); Herrmann et al., *Proc. Natl. Acad. Sci. USA* 78:2488-2492, 1981; Herrmann et al., *J. Immunol.* 128:1968-1974, 1982; Handa et al., *J. Immunol.* 135:1564-1572, 1985; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Takai et al., *J. Immunol.* 140:508-512, 1988; Herrmann et al., *Proc. Natl. Acad. Sci. USA* 78:2488-2492, 1981; Herrmann et al., *J. Immunol.* 128:1968-1974, 1982; Handa et al., *J. Immunol.* 135:1564-1572, 1985; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Bowman et al., *J. Virology* 61:1992-1998; Takai et al., *J. Immunol.* 140:508-512, 1988; Bertagnoli et al., *Cellular Immunology* 133:327-341, 1991; Brown et al., *J. Immunol.* 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, *J. Immunol.* 144:3028-3033, 1990; and Assays for B cell function: *In vitro* antibody production, Mond, J.J. and Brunswick, M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates

and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

- 5 Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

- 15 Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 20 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad. Sci. USA 88:7548-7551, 1991.

25

Hematopoiesis Regulating Activity

- A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines 30 indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as

granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelosuppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. *Cellular Biology* 15:141-151, 1995; Keller et al., *Molecular and Cellular Biology* 13:473-486, 1993; McClanahan et al., *Blood* 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., *Proc. Natl. Acad. Sci. USA* 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., *Experimental Hematology* 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 163-179,

Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland, H.J. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

5 Tissue Growth Activity

A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

10 A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. *De novo* bone
15 formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract
20 bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

25 Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and
30 other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. *De novo* tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma

induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors
5 of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

10 The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral
15 nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and
20 cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with
25 vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells
30 comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting
5 differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for tissue generation activity include, without limitation, those described in:

10 International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

Assays for wound healing activity include, without limitation, those described in:

Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year
15 Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

Activin/Inhibin Activity

A protein of the present invention may also exhibit activin- or inhibin-related
20 activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin α family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and
25 decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin- β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States
30 Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.

5

Chemotactic/Chemokinetic Activity

A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells.

10 Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against
15 the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population
20 of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent
25 chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene
30 Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

Hemostatic and Thrombolytic Activity

A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other
5 hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

The activity of a protein of the invention may, among other means, be measured
10 by the following methods:

Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

Receptor/Ligand Activity

A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands,
20 receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of
25 potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

The activity of a protein of the invention may, among other means, be measured by the following methods:

30 Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987;

Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

5 Anti-Inflammatory Activity

Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

20

Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

30

Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious

agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

20

ADMINISTRATION AND DOSING

A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF α , TNF β , TNF γ , G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or complement its activity or

use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain

physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 μ g to about 100 mg (preferably about 0.1 μ g to about 10 mg, more preferably about 0.1 μ g to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending

physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. Such antibodies may
5 be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer.Chem. Soc. 85, 2149-2154 (1963); J.L. Krstenansky, *et al.*, FEBS Lett. 211, 10
10 (1987). Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic
15 cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the
20 composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair.
25 Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site
30 of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular

application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.

A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- α and TGF- β), and insulin-like growth factor (IGF).

The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.

5 The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of
10 matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.

15 Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).

20 Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes.

25 Patent and literature references cited herein are incorporated by reference as if fully set forth.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Jacobs, Kenneth
McCoy, John
LaVallie, Edward
Racie, Lisa
Merberg, David
Treacy, Maurice
Spaulding, Vicky
- (ii) TITLE OF INVENTION: SECRETED PROTEINS AND POLYNUCLEOTIDES
ENCODING THEM
- (iii) NUMBER OF SEQUENCES: 25
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Genetics Institute, Inc.
 - (B) STREET: 87 CambridgePark Drive
 - (C) CITY: Cambridge
 - (D) STATE: MA
 - (E) COUNTRY: USA
 - (F) ZIP: 02140
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Brown, Scott A.
 - (B) REGISTRATION NUMBER: 32,724
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (617) 493-8224
 - (B) TELEFAX: (617) 876-5851

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 162 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAATTCGGCC AAAGAGGCCT AGTGATATTA TAGTGTA GTT TTTAGATGT TACCATTGGG 60
 AGAAACTGAG TAAAGAAGAT GTGGGATCTT TCTTTAGTAT TTCTTAGAAC TGCATGTGAA 120
 TCTACAATA GCTCAAAATA AAAAGTTTAA TTATAAATAA AA 162

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1014 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TTTGGGCTCA GTGAATTGTC TTCTTCAGGA GGGTAATTTT CTCTTCCTTC TCTGCTAAGC 60
 TGTTTAACAG TAGTTGCCCT GCCTAATGGG CTTCATCCAT CCATTTCTCT CAGATTATTT 120
 TCATGATGCA CTAGGATGAA GCACACCCTT TCTCCTAGTC TTGAGGAAAC GTCGATATTC 180
 AGAATATTTA AACGCAGGCA CTGACCAATC AGAAGAGTTT CTGGCCAACG TTCCACACTT 240
 GAGGGAAATG ACATTATCTG AGCCCTGAAG AAAAACGTTG TAGATATTCT CCAGATCAAA 300
 GCATCGACAG GAAGATTTTA GATGTTGAAG TTCGTAATAT TTCCTAAAGC AGGTTGTGTG 360
 CATTCAAARG AGMAKTCTAT TAAAGCTACC YTMNWTGGC GCTTATTTTT CTTAATCATG 420
 TTTCTGACAA TCATAGTGTG TGGAGRGGT TGCTGCTTTA AGYGCAATAA GAGCTAWCTG 480
 CCATCAAGAG CCATCAGTAT GTCTTCGAGC TGCATGCCCA GAAAGCTGGA TTGTTTTTCA 540
 AACGAAAGTG TYTCTATTTT TCTGATGACR CCAAGAACT GGACATCAAG TCAGAGGKKT 600
 TGTGACTCAC AAGATGCTGA TCTTGCTCAG GTTGAAAGCT TCCAGGAACT GAATTCCTG 660
 TTGAGAKATA AAGGCCCATC TGATCACTGG ATTGGGCTGA GCANAGAACA NGGCCAACCA 720
 TGGAAATGGA TAAATGGTAC TGAATGGACA ANACAGTTTC CTATCCTGGG AGCAGGANAN 780
 TGTGCCTATT TGAATGACAA AGGTGCCAGT AGTGCCAGGC ACTACACAGA GAGGAANTGG 840
 ATTTGTNCCA AATCANATNT NCTTNTCTAN ATGTTACAGC AAAGCCCCAA CTAATCTTTA 900
 NAAGCATATT GGAAGTATA ACTCCATTTT AAAATGAGCA AANANTTTAT TTCTTATNCC 960
 AACNGGTATA TGAAAATATG CTCNATNTCA CTAATAACTG GGAAAATAAC CNTT 1014

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 338 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Phe Gly Leu Ser Glu Phe Ala Ser Ser Gly Gly Xaa Phe Ser Leu Leu
1           5           10           15
Ser Leu Leu Ser Cys Leu Thr Val Val Ala Leu Pro Asn Gly Leu His
20           25           30
Pro Ser Ile Ser Leu Arg Leu Phe Ser Xaa Cys Thr Arg Met Lys His
35           40           45
Thr Leu Ser Pro Ser Leu Glu Glu Thr Ser Ile Phe Arg Ile Phe Lys
50           55           60
Arg Arg His Xaa Pro Ile Arg Arg Val Ser Gly Gln Arg Ser Thr Leu
65           70           75           80
Glu Gly Asn Asp Ile Ile Xaa Ala Leu Lys Lys Asn Val Val Asp Ile
85           90           95
Leu Gln Ile Lys Ala Ser Thr Gly Arg Phe Xaa Met Leu Lys Phe Val
100          105          110
Ile Phe Pro Lys Ala Gly Cys Val His Ser Lys Glu Xaa Ser Ile Lys
115          120          125
Ala Thr Xaa Xaa Trp Arg Leu Phe Phe Leu Ile Met Phe Leu Thr Ile
130          135          140
Ile Val Cys Gly Xaa Gly Cys Cys Phe Lys Xaa Asn Lys Ser Xaa Leu
145          150          155          160
Pro Ser Arg Ala Ile Ser Met Ser Ser Ser Cys Met Pro Arg Lys Leu
165          170          175
Asp Cys Phe Ser Asn Glu Ser Val Ser Ile Phe Leu Met Thr Pro Arg
180          185          190
Asn Trp Thr Ser Ser Gln Arg Xaa Cys Asp Ser Gln Asp Ala Asp Leu
195          200          205
Ala Gln Val Glu Ser Phe Gln Glu Leu Asn Phe Leu Leu Arg Xaa Lys
210          215          220
Gly Pro Ser Asp His Trp Ile Gly Leu Ser Xaa Glu Xaa Gly Gln Pro
225          230          235          240
Trp Lys Trp Ile Asn Gly Thr Glu Trp Thr Xaa Gln Phe Pro Ile Leu
245          250          255
Gly Ala Gly Xaa Cys Ala Tyr Leu Asn Asp Lys Gly Ala Ser Ser Ala
260          265          270
Arg His Tyr Thr Glu Arg Xaa Trp Ile Cys Xaa Lys Ser Xaa Xaa Leu
275          280          285
Xaa Xaa Met Leu Gln Gln Ser Pro Asn Xaa Ser Leu Xaa Ala Tyr Trp

```

290 295 300

Asn Xaa Xaa Leu His Phe Lys Met Ser Lys Xaa Phe Ile Ser Tyr Xaa
 305 310 315 320

Asn Xaa Tyr Met Lys Ile Cys Ser Xaa Ser Leu Ile Thr Gly Lys Ile
 325 330 335

Thr Xaa

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 177 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ATATGCTCAA TATCACTAAT AACTGGGAAA TACAAATCAA AATCATAGTA AAATATTACC 60

TGTTTTTCATG GTGCTAATAT TACCTGTTCT CCCACTGCTA ATGACATACC CGAGACTGAG 120

TAATTTATAA ATAAAAGAGA TTAAATTGAA AAAAAAAAAA AAAAAAAAAA AAAAAAA 177

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 325 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TCTTTCTTTT TTCTCCCCTT TACTCTTTGG GTGGTGTTC TTTTCCTTTC CTTTCCCTT 60

TGARATTTT TTGTTGTGTG TTCTTTTGT TATTTTACTG ATATCACCAG NATAGTTTAC 120

TCTCCTTCTA GCTTTCTGCT TACCGCACAC TGGATAACAC ACACATACAC ACCCAGAAAA 180

ATGCTCATGA ACCCAATCCG GAGAAGGTTT CAGCAGGTCC CCCACCCTCC CCTCCTCCTC 240

CTACTTCTCC TCTTGACAGC GAGGACAGGA GGGGGACAAG GGGACACCTG GGCAGACCCG 300

CCGGCTCTCC CCCACCCCA CCCCCG 325

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

Met Leu Met Asn Pro Ile Arg Arg Arg Phe Gln Gln Val Pro His Pro
 1             5             10             15

Pro Leu Leu Leu Leu Leu Leu Leu Thr Ala Arg Thr Gly Gly Gly
      20             25             30

Gln Gly Asp Thr Trp Ala Asp Pro Pro Ala Leu Pro Pro Pro His Pro
      35             40             45

```

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 101 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

TATGTTTGA TTTTAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA    60
AAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA A                101

```

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 522 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```

GAATTCGGCA AAGAGCTANG AATTCGTTAT CCGCGATGCG TTTCCTGGCA GCTACATTCC    60
TGCTCCTGGC GCTCAGCACC GCTGCCCAGG CCGAACCGGT GCAGTTCAAG GACTGCGGTT    120
CTGTGGATGG AGTTATAAAG GAAGTGAATG TGAGCCCATG CCCCACCCAA CCCTGCCAGC    180

```

TGAGCAAAGG ACAGTCTTAC AGCGTCAATG TCACCTTCAC CAGCAATATT CAGTCTAAAA 240
 GCAGCAAGGC CGTGGTGCAT GGCATCCTGA TGGGCGTCCC AGTTCCTTT CCCATTCCCTG 300
 AGCCTGATGG TTGTAAGAGT GGAATTAAC TCCCTATCCA AAAAGACAAG ACCTATAGCT 360
 ACCTGAATAA ACTACCAAGT AAAAGCGAAT ATCCCTCTAT AAAACTGGTG GTGGAGTGGC 420
 AACTTCAGGA TGACAAAAAC CAAATCTCTT CTGCTGGGAA ATCCCAGTNC AGATCGTTTC 480
 TCATCTCTAA GTGCCTCATT GAGTTCGGTG CATCTGGGCC AA 522

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 162 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Met Arg Phe Leu Ala Ala Thr Phe Leu Leu Leu Ala Leu Ser Thr Ala
 1 5 10 15
 Ala Gln Ala Glu Pro Val Gln Phe Lys Asp Cys Gly Ser Val Asp Gly
 20 25 30
 Val Ile Lys Glu Val Asn Val Ser Pro Cys Pro Thr Gln Pro Cys Gln
 35 40 45
 Leu Ser Lys Gly Gln Ser Tyr Ser Val Asn Val Thr Phe Thr Ser Asn
 50 55 60
 Ile Gln Ser Lys Ser Ser Lys Ala Val Val His Gly Ile Leu Met Gly
 65 70 75 80
 Val Pro Val Pro Phe Pro Ile Pro Glu Pro Asp Gly Cys Lys Ser Gly
 85 90 95
 Ile Asn Cys Pro Ile Gln Lys Asp Lys Thr Tyr Ser Tyr Leu Asn Lys
 100 105 110
 Leu Pro Val Lys Ser Glu Tyr Pro Ser Ile Lys Leu Val Val Glu Trp
 115 120 125
 Gln Leu Gln Asp Asp Lys Asn Gln Ile Ser Ser Ala Gly Lys Ser Gln
 130 135 140
 Xaa Arg Ser Phe Leu Ile Ser Lys Cys Leu Ile Glu Phe Gly Ala Ser
 145 150 155 160
 Gly Pro

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 259 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

```
TTTGTAGCAG AAAATGNGCT CCGGGNGGNT GGTTTTCAGG GGGTGTNTCA AGTTTNTTTT    60
TCTGTTTTAG GGGGNTTCAT TAAANGCAGC ANTTGGTTAG CAGANGTTTA ATTTTTTTTT    120
TAACAANATT AAATTGNGGC CTCTTTTAC ANCTGGNAAT TNANTTTTGN ATAAATAAAA    180
AATNGTTTGT TTTGTCCAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA    240
AAAAAAAAAA AAAAAAAG                                     259
```

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 499 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

```
AGCAANAAAC CAGTCAACTC ATGCACNCGA GCGGTNCANG AAACCAACAA AAATAACTCT    60
GAGAGCATAG AATGCAGAAA AATAACAATG GATCTCAATT TCAACCANTC CAGAAAAANAT    120
ATCTCTATCA CTGTNCCATC CAAAACCCAA ACAATGTCAC CACACATCAA GTCAGTTGAC    180
GACGTTGTGG TACTTGGCAT GAATCTCAGC AAGTTTAAAC AACTTACTCA GTTTTTCATA    240
TGTGTTGCTG GAGTTTTTGT ATTTTACCTA ATTTATGGGT ATTTACAGGA ATTAATATTT    300
TCAGTGGAGG GTTTTAAGTC CTGTGGCTGG TACCTTACCT TAGTGCAGTT TGCCTTTTAC    360
TCCATATTTG GCCTAATAGA ACTTCAGCTT ATTCAGGACA AAAGGAGGAG AATACCAGGA    420
AAAAACCTAC ATGATAATAG CTTTCTAAC TGTGGGTACT ATGGGGNNGG CAAACACTTC    480
CTTGGGCTAC CTGAATTAC                                     499
```

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 137 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```

Met Asp Leu Asn Phe Asn Xaa Ser Arg Lys Xaa Ile Ser Ile Thr Val
 1             5             10             15
Pro Ser Lys Thr Gln Thr Met Ser Pro His Ile Lys Ser Val Asp Asp
          20             25             30
Val Val Val Leu Gly Met Asn Leu Ser Lys Phe Asn Lys Leu Thr Gln
          35             40             45
Phe Phe Ile Cys Val Ala Gly Val Phe Val Phe Tyr Leu Ile Tyr Gly
          50             55             60
Tyr Leu Gln Glu Leu Ile Phe Ser Val Glu Gly Phe Lys Ser Cys Gly
          65             70             75             80
Trp Tyr Leu Thr Leu Val Gln Phe Ala Phe Tyr Ser Ile Phe Gly Leu
          85             90             95
Ile Glu Leu Gln Leu Ile Gln Asp Lys Arg Arg Arg Ile Pro Gly Lys
          100             105             110
Asn Leu His Asp Asn Ser Phe Ser Asn Cys Gly Tyr Tyr Gly Xaa Gly
          115             120             125
Lys His Phe Leu Gly Leu Pro Glu Leu
          130             135

```

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 438 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

```

ACTTTCCTCAA GGGATGATAA AACCAAAGAA TTGGAGGCAT TGTATCCCAT TTGTGGACAG      60
ATTTTCATATG AAGTTGTTTT GCGGTGTCAG CCTTTTTCCT AGAGCATTTG TTGACTGAC      120
TTCCAAAGCA ATCAAGAGAG CCACGTCTAG CAGACTTTAC AATAAAATGT CAATATGAAG      180
GACTGTAATT CCTAGCAGTT TATTGAGAAT TTCACTGGAA ATGGACCATG TGTGCAAGA      240
CTAATTGGCT ATAATTATAT CCTATCAAAG AAATCGATAC GTAATAGCAG ATTGTTTAT      300
ATTCATTCCA TTTGATGGT GTTATTTAAA TTGTTCTCTG TTATAAGAGT AAAGTATGA      360

```

GTTGAAGTCT GGAGAGAATA ACATTCATTA TAAATAAAAT TATTCTGTGT CTTTTTCAAA 420
 AAAAAAAAAA AAAAAAAAAA 436

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 479 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GTGGGATTTA ATTAAGAATT NGGCCCCAAG AGGCCTAACA GGATCAACAC ATTTTCATCTG 60
 GGCTTCTTAA ATCTAAATCT TTAATGAC TAAGTTTCT TCCTTTTCTC TGTTTTCTC 120
 AATAGTTGGG GCTTAATATG ACTCATGTGT GTTCAATAT GGAAATTATT GGAGGGAAAG 180
 AAGTGTCAAC TCATTCCAGG CCANTTATGG CCTCCATCCA GTATGGCGGA CATCACGTTT 240
 GTGGAGGTGT TCTGATTGAT CCACAGTGGG TGCTGACAGC AGCCCACTGC CAATATCGGT 300
 TTACCAAAGG CCAGTCTCCC ACTGTGGTTT TAGGCGCACA CTCTCTCTCA AAGAATGAGG 360
 CCTCCAAACA AACACTGGAG ATCAAAAAAT TTATACCATT CTCAAGAGTT ACATCAGATC 420
 CTCAATCCAA TGATATCATG CTGGTTAAGC NTCAAACAGC CGCCAAACTC AATAAACAT 479

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 114 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Met Thr His Val Cys Phe Asn Met Glu Ile Ile Gly Gly Lys Glu Val
 1 5 10 15
 Ser Pro His Ser Arg Pro Xaa Met Ala Ser Ile Gln Tyr Gly Gly His
 20 25 30
 His Val Cys Gly Gly Val Leu Ile Asp Pro Gln Trp Val Leu Thr Ala
 35 40 45
 Ala His Cys Gln Tyr Arg Phe Thr Lys Gly Gln Ser Pro Thr Val Val
 50 55 60

Leu Gly Ala His Ser Leu Ser Lys Asn Glu Ala Ser Lys Gln Thr Leu
 65 70 75 80
 Glu Ile Lys Lys Phe Ile Pro Phe Ser Arg Val Thr Ser Asp Pro Gln
 85 90 95
 Ser Asn Asp Ile Met Leu Val Lys Xaa Gln Thr Ala Ala Lys Leu Asn
 100 105 110
 Lys His

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 173 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GCAGGTTAGA GTTGGTGTAG TAAAGCAGAG CACATATGGG TCCATTTTGC ACTTGTAAGT 60
 CATTTTATTA AGGAATCAAG TTCTTTTTC A CTGTATCAC TGATGTATTT CTACCATGCT 120
 GGTTTTATTC TAAATAAAAT TTAGAAGACT CTCAAAAAAA AAAAAAAAAA AAA 173

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 461 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CGATAATCTT CTTCATTG NGGGGAAATT TATGTCATCC TTCTTTAAAC CGGGGTTTGA 60
 GAAGTATNAT AACTTGGATC TNTNTCGNA TCTCTTAAAT ATTCCAGGAC CAATTGACAN 120
 NCCATCTCGA ATTCGGCCAA AGAGGCCTAG ATGATGATAT GTTTAACCAC CAAGTTCCTT 180
 ATTTGTGGCT GATTTACTGC CTTTGTATC CTCTTCAATC AAGTATTAAA GAAACAGTGG 240
 AGGCATATGA GGCAGCATTA GGGGTGGCTA TGAGATGTGA TATAGTACAG AAGATATGGA 300
 TGGATTATCT TGTCTTTGCA AATAATAGAG CTGCTGGATC CAGAAACAAA GTTCAAGAAT 360
 TCAAATTTT TACTGATTTA GTGAATAGAT GTTTGGTTAC AGTCCCTGCC CGATACCCCA 420

TTCCTTTTAG CAGTGCTGAT TACTGGTCCA ACTATGAATT T

461

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 101 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

```

Met Phe Asn His Gln Val Pro Tyr Leu Trp Leu Ile Tyr Cys Leu Cys
 1             5             10             15

His Pro Leu Gln Ser Ser Ile Lys Glu Thr Val Glu Ala Tyr Glu Ala
 20             25             30

Ala Leu Gly Val Ala Met Arg Cys Asp Ile Val Gln Lys Ile Trp Met
 35             40             45

Asp Tyr Leu Val Phe Ala Asn Asn Arg Ala Ala Gly Ser Arg Asn Lys
 50             55             60

Val Gln Glu Phe Lys Phe Phe Thr Asp Leu Val Asn Arg Cys Leu Val
 65             70             75             80

Thr Val Pro Ala Arg Tyr Pro Ile Pro Phe Ser Ser Ala Asp Tyr Trp
 85             90             95

Ser Asn Tyr Glu Phe
 100

```

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 318 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

```

TTTTTTGAGA TTCTTCATTT CGGGATTITA AACNATAGC AGNCCATCTT AAGGAAAGTG      60
TANCTNCCAT GGCCACAAGT CTGCTAGTTG CACTTGAATG CTCTATCNGG GTTGTTTATT      120
ACCTTTTCNA CGTTCTGGAC TCCTTTCCGA GACTGTTTAA CTTGNAGATT AAAGAAACTA      180
TTCCAAATGC CAGTGCATCA GNACCTAAGA GTGGGCAAAT ATTATGTGCA ATTTTTTTGT      240
AAAGAAATTT TAATTTATAA TAAAGTTTAA CAGTTTAAAG GNCCCCAAAA AAAAAAAAAA      300

```

AAAAAAAAAA AAAAAAAAAA

318

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CCATCAGTAT GTCTTCGAGC TGCATGC

27

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

ATGCTCATGA ACCCAATCCG GAGAAGG

27

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GCTCAGGAAT GGGAAAGGGA ACTGGGA

27

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CATGATAATA GCTTTTCTAA CTGTGGGTAC

30

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

GTGGTTTTAG GCGCACACTC TCTCTCA

27

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 45 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

AAAGGCAGTA AATCAGCCAC AAATAAGGAA CTTGGTGGTT AAACA

45

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1560 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GTGATATTAT AGTGTAGTTT TTTAGATGTT ACCATTGGGA GAAACTGAGT AAAGAAGATG	60
TGGGATCTTT CTTTAGTATT TCTTAGAACT GCATGTGAAT CTACAAC TAG CTCAAATAA	120
AAAGTTTAAAT TATAAAATAA AAGCTACATG AAATGAAGCA AAAAATAATT CACCCTTGTC	180
ACGCACACAG AGTCAGAGAC TGTAACATAA TTTGCAGGAT CTAGAGCAGA ATACAAATGT	240
AAAACATCTT GTTAAAAAAT TATTAATAAT TTTGAGACAT TGATAAGCA TTAAGCCGCC	300
TGTGGGGCCC TTTAAGCATG ATAACTGTG CTACCACACA GATTGCACAT TCACGTATCT	360
GGCCCTGCAA ATGGAATGAT TTTTGGCCAT GATCAATTCA CCATGGCCTC TTTGGGCTCA	420
GTGAATTTGC TTCTTCAGGA GGGTAATTTT CTCTTCTTTC TCTGCTAAGC TGTTTAAACAG	480
TAGTTGCCCT GCCTAATGGG CTTCATCCAT CCATTTCTCT CAGATTATTT TCATGATGCA	540
CTAGGATGAA GCACACCCTT TCTCCTAGTC TTGAGGAAAC GTCGATATTC AGAATATTTA	600
AACGCAGGCA CTGACCAATC AGAAGAGTTT CTGGCCAACG TTCCACACTT GAGGGAAATG	660
ACATTATCTG AGCCCTGAAG AAAACGTTG TAGATATTCT CCAGATCAAA GCATCGACAG	720
GAAGATTTTA GATGTTGAAG TTCGTAATAT TTCCTAAAGC AGGTTGTGTG CATTCAAAAG	780
AGCATTCTAT TAAAGCTACC TTAATTTGGC GCTTATTTTT CTTAATCATG TTTCTGACAA	840
TCATAGTGTG TGGAATGGTT GCTGCTTAA GTGCAATAAG AGCTAACTGC CATCAAGAGC	900
CATCAGTATG TCTTCAAGCT GCATGCCCAG AAAGCTGGAT TGGTTTTCAA AGAAAGTGT	960
TCTATTTTTT TGATGACACC AAGAACTGGA CATCAAGTCA GAGGTTTGT GACTCACAAG	1020
ATGCTGATCT TGCTCAGGTT GAAAGCTTCC AGGAACTGAA TTTCCTGTTG AGATATAAG	1080
GCCCATCTGA TCACTGGATT GGGCTGAGCA GAGAACAAG CCAACCATGG AAATGGATAA	1140
ATGGTACTGA ATGGACAAGA CAGTTTCCTA TCCTGGGAGC AGGAGAGTGT GCCTATTTGA	1200
ATGACAAAGG TGCCAGTAGT GCCAGGCACT ACACAGAGAG GAAGTGGATT TGTCCAAAT	1260
CAGATATACA TGTCTAGATG TTACAGCAA GCCCCAATA ATCTTTAGAA GCATATTGGA	1320
ACTGATAACT CCATTTTAAA ATGAGCAAAG AATTTATTTT TTATACCAAC AGGTATATGA	1380
AAATATGCTC AATATCACTA ATAACTGGGA AAATACAAAT CAAAATCATA GTAAATATT	1440
ACCTGTTTTT ATGGTGCTAA TATTACCTGT TCTCCCACTG CTAATGACAT ACCCGAGACT	1500
GAGTAATTTA TAAATAAAAG AGATTTAATT GAAAAAAAAA AAAAAAAAAA AAAAAAAAAA	1560

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 181 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Met Leu Lys Phe Val Ile Phe Pro Lys Ala Gly Cys Val His Ser Lys
 1 5 10 15
 Glu His Ser Ile Lys Ala Thr Leu Ile Trp Arg Leu Phe Phe Leu Ile
 20 25 30
 Met Phe Leu Thr Ile Ile Val Cys Gly Met Val Ala Ala Leu Ser Ala
 35 40 45
 Ile Arg Ala Asn Cys His Gln Glu Pro Ser Val Cys Leu Gln Ala Ala
 50 55 60
 Cys Pro Glu Ser Trp Ile Gly Phe Gln Arg Lys Cys Phe Tyr Phe Ser
 65 70 75 80
 Asp Asp Thr Lys Asn Trp Thr Ser Ser Gln Arg Phe Cys Asp Ser Gln
 85 90 95
 Asp Ala Asp Leu Ala Gln Val Glu Ser Phe Gln Glu Leu Asn Phe Leu
 100 105 110
 Leu Arg Tyr Lys Gly Pro Ser Asp His Trp Ile Gly Leu Ser Arg Glu
 115 120 125
 Gln Gly Gln Pro Trp Lys Trp Ile Asn Gly Thr Glu Trp Thr Arg Gln
 130 135 140
 Phe Pro Ile Leu Gly Ala Gly Glu Cys Ala Tyr Leu Asn Asp Lys Gly
 145 150 155 160
 Ala Ser Ser Ala Arg His Tyr Thr Glu Arg Lys Trp Ile Cys Ser Lys
 165 170 175
 Ser Asp Ile His Val
 180

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 605 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

TAGGACAAAA CAAACATTT TCCCTGGGG TTTTTTTTTT CTTCTTTTT TCTCCCCTTT 60
 ACTCTTGGG TGGTGTGCT TTTCCTTCC TTTCCCTTT GAGATTTTT TGTTGTTGTT 120
 TCCTTTTGT ATTTTACTGA TATCACCAGG ATAGTTTACT CTCCTTCTAG CTTTCTGCTT 180

ACCGCACACT GGATAACACA CACATACACA CCCACAAAAA TGCTCATGAA CCCAATCCGG 240
 AGAAGGTTCC AGCAGGTCCC CCACCCTCCC CTCCTCCTCC TACTTCTCCT CTTGACAGCG 300
 AGGACAGGAG GGGGACAAGG GGACACCTGG GCAGACCCGC CGGCTCTCCC CCCACCCAC 360
 CCCGCCCTC ACATCATACT CCAATCATAA CCTTGATAT TACGCAGTCA TTTTGGTTT 420
 CGCGGACGCG CCTACCTAAG TACCATTAC AGAAAGTGAC TCTGGCTGTC ATTATTTGT 480
 TTATTTGTTT CCTATGCAAA AAAAAATGA AAATGAAAAA AGGGGGATTC CATAAAGAT 540
 TCAATAAAG ACAAAAAAAG AGAAAAAGA AAAAAATGTA TAAAAATTAA AAAAAA 600
 AAAAA 605

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 139 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Leu Ser Ala Tyr Arg Thr Leu Asp Asn Thr His Ile His Thr His Lys
 1 5 10 15
 Asn Ala His Glu Pro Asn Pro Glu Lys Val Pro Ala Gly Pro Pro Pro
 20 25 30
 Ser Pro Pro Pro Thr Ser Pro Leu Asp Ser Glu Asp Arg Arg Gly
 35 40 45
 Thr Arg Gly His Leu Gly Arg Pro Ala Gly Ser Pro Pro Thr Pro Pro
 50 55 60
 Arg Pro Ser His His Thr Pro Ile Ile Thr Leu Tyr Ile Thr Gln Ser
 65 70 75 80
 Phe Trp Phe Ser Arg Thr Arg Leu Pro Lys Tyr His Leu Gln Lys Val
 85 90 95
 Thr Leu Ala Val Ile Ile Leu Phe Ile Cys Ser Leu Cys Lys Lys Lys
 100 105 110
 Met Lys Met Lys Lys Gly Gly Phe His Lys Arg Phe Asn Lys Arg Gln
 115 120 125
 Lys Lys Arg Lys Lys Lys Lys Met Tyr Lys Asn
 130 135

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 863 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

GGAAGTTCGT TATCCGCGAT GCGTTTCCTG GCAGCTACAT TCCTGCTCCT GGCCTCAGC	60
ACCGCTGCCC AGGCCGAACC GGTGCAGTTC AAGGACTGCG GTTCTGTGGA TGGAGTTATA	120
AAGGAAGTGA ATGTGAGCCC ATGCCCCACC CAACCTGACC AGCTGAGCAA AGGACAGTCT	180
TACAGCGTCA ATGTCACCTT CACCAGCAAT ATTCAGTCTA AAAGCAGCAA GGCCGTGGTG	240
CATGGCATCC TGATGGGCGT CCCAGTCCCC TTCCCATTC CTGAGCCTGA TGGTTGTAAG	300
AGTGGAATTA ACTGCCCTAT CAAAAAGAC AAGACCTATA GCTACCTGAA TAACTACCA	360
GTGAAAAGCG AATATCCCTC TATAAACTG GTGGTGGAGT GGCAACTTCA GGATGACAAA	420
AACCAAAGTC TCTTCTGCTG GGAAATCCCA GTACAGATCG TTTCTCATCT CTAAGTGCCT	480
CATTGAGTTC GGTGCATCTG GCCAATGAGT CTGCTGAGAC TCTTGACAGC ACCTCCAGCT	540
CTGCTGCTTC AACAAAGTGT ACTTGCTCTC CAATGGTATC CAGTGATTCG TTGAAGAGGA	600
GGTGCTCTGT AGCAGAAACT GAGCTCCGGG TGGCTGGTTC TCAGTGGTTG TCTCATGTCT	660
CTTTTCTGT CTTAGGTGGT TTCATTAAAT GCAGCACTTG GTTAGCAGAT GTTTAATTTT	720
TTTTTAAACA ACATTAAGTT GTGGCCTCTT TCTACACCTG GAAATTTACT CTTGAATAAA	780
TAAAACTCG TTTGTCTTGT CAAAAA AAAA AAAA AAAA	840
AAAAA AAAA AAAA	863

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 151 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Met	Arg	Phe	Leu	Ala	Thr	Phe	Leu	Leu	Ala	Leu	Ser	Thr	Ala
1			5				10				15		
Ala	Gln	Ala	Glu	Pro	Val	Gln	Phe	Lys	Asp	Cys	Gly	Ser	Val
			20				25				30		

Val Ile Lys Glu Val Asn Val Ser Pro Cys Pro Thr Gln Pro Cys Gln
 35 40 45
 Leu Ser Lys Gly Gln Ser Tyr Ser Val Asn Val Thr Phe Thr Ser Asn
 50 55 60
 Ile Gln Ser Lys Ser Ser Lys Ala Val Val His Gly Ile Leu Met Gly
 65 70 75 80
 Val Pro Val Pro Phe Pro Ile Pro Glu Pro Asp Gly Cys Lys Ser Gly
 85 90 95
 Ile Asn Cys Pro Ile Gln Lys Asp Lys Thr Tyr Ser Tyr Leu Asn Lys
 100 105 110
 Leu Pro Val Lys Ser Glu Tyr Pro Ser Ile Lys Leu Val Val Glu Trp
 115 120 125
 Gln Leu Gln Asp Asp Lys Asn Gln Ser Leu Phe Cys Trp Glu Ile Pro
 130 135 140
 Val Gln Ile Val Ser His Leu
 145 150

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1575 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

CATAACAGTC CAGGAAACCA ACAAATAA CTCTGAAAGC ATTGAATGCA GCAAATAAC 60
 AATGGATCTC AAGTTCAACA ATTCCAGGAA ATATATTCT ATCACTGTGC CATCCAAAC 120
 CCAAACAATG TCACCACACA TCAAGTCAGT TGACGACGTT GTGGTACTTG GCATGAATCT 180
 CAGCAAGTTT AACAACTTA CTCAGTTTTT CATATGTGTT GCTGGAGTTT TTGTATTTTA 240
 CCTAATTTAT GGGTATTTAC AGGAATTAAT ATTTTCAGTG GAGGGTTTTA AGTCCTGTGG 300
 CTGGTACCTT ACCTTAGTGC AGTTTGCCTT TTA CTCCATA TTTGGCCTAA TAGAACTTCA 360
 GCTTATTCAG GACAAAAGGA GGAGAATACC AGGAAAAACC TACATGATAA TAGCTTTTCT 420
 AACTGTGGGT ACTATGGGGT TATCAACAC TTCCTGGGC TACCTGAATT ACCCTACCCA 480
 AGTCATCTTC AAGTGCTGCA AATTGATTCC TGTATGCTA GGAGGAGTTT TTATTCAAGG 540
 AAAGCGTTAT AATGTTGCAG ATGTGTCTGC TGCCATATGT ATGAGCCTTG GCCTGATATG 600
 GTTTACCCTC GCTGACAGCA CAACTGCACC AAATTTCAAC CTGCGGGTAT TGTATTCGTA 660
 TTCAATTGGT TTTGTATACA TTTTACTGGG ATTGACATGC ACTAGTGGAT TAGGCCCTGC 720


```

AGTAACATTT TGTGCAAAGA ATCCAGTTCG GACCTATGGT TATGCGTTCC TTTTTCCTT      780
CACTGGATAT TTTGGAATCT CCTTTGTTCT GGCTTTGATT AAAATTTTGT GTGCATTAT      840
TGCTGTAACA GTGACAACAG GAAGAAAAGC AATGACCATT GTACTTTCGT TTATATTCTT      900
TGCTAAACCA TTCACGTTTC AGTATGTATG GTCTGGTTTG TTAGTTGTCC TTGGTATATT      960
TCTCAATGTT TACAGCAAAA ATATGGATAA AATAAGACTA CCATCACTGT ATGATTTGAT     1020
AAACAAATCA GTGGAAGCAA GAAAGTCAAG GACGCTGGCA CAGACTGTAT AGACAGTGAT     1080
TGCCTATTTT AAAATAGAAT TTAAAGGGAA CAATCATCAA TTAATTAAC TCCAAAGGG      1140
ACTGATAAAA ACCAAAGGAT CTGGAGGCAT TGCTATCCCA TTTGTGGACA GATTCATAT      1200
GAAGTTGTTT TCGGTTGTCA GCCTTTTCTT CAGAGCATTT GTTTGACTGA CTTCCAAAGC     1260
AATCAAGAGA GCCACGTCTA GCAGACTTTA CAATAAAATG TCAATATGAA GGACTGTAAT     1320
TCCTAGCAGT TTATTGAGAA TTCACTGGA AATGGACCAT GTGTTGCAAG ACTAATTGGC     1380
TATAATTATA TCCTATCAAA GAAATCGATA CGTAATAGCA GATTGTTTTA TATTCATTCC     1440
ATTTTGATGG TGTTATTTAA ATTGATTCTC TGTATAAGA GTAAACTGAT GAGTTGAAGT     1500
CTGGAGAGAA TAACATTCAT TATAAATAAA ATTATTCTGT GATCTTTTTT CAAAAAAAAA     1560
AAAAAAAAAA AAAAAA                                     1575

```

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 336 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

```

Met Asp Leu Lys Phe Asn Asn Ser Arg Lys Tyr Ile Ser Ile Thr Val
1           5           10           15
Pro Ser Lys Thr Gln Thr Met Ser Pro His Ile Lys Ser Val Asp Asp
20          25          30
Val Val Val Leu Gly Met Asn Leu Ser Lys Phe Asn Lys Leu Thr Gln
35          40          45
Phe Phe Ile Cys Val Ala Gly Val Phe Val Phe Tyr Leu Ile Tyr Gly
50          55          60
Tyr Leu Gln Glu Leu Ile Phe Ser Val Glu Gly Phe Lys Ser Cys Gly
65          70          75          80
Trp Tyr Leu Thr Leu Val Gln Phe Ala Phe Tyr Ser Ile Phe Gly Leu
85          90          95

```

Ile Glu Leu Gln Leu Ile Gln Asp Lys Arg Arg Arg Ile Pro Gly Lys
 100 105 110
 Thr Tyr Met Ile Ile Ala Phe Leu Thr Val Gly Thr Met Gly Leu Ser
 115 120 125
 Asn Thr Ser Leu Gly Tyr Leu Asn Tyr Pro Thr Gln Val Ile Phe Lys
 130 135 140
 Cys Cys Lys Leu Ile Pro Val Met Leu Gly Gly Val Phe Ile Gln Gly
 145 150 155 160
 Lys Arg Tyr Asn Val Ala Asp Val Ser Ala Ala Ile Cys Met Ser Leu
 165 170 175
 Gly Leu Ile Trp Phe Thr Leu Ala Asp Ser Thr Thr Ala Pro Asn Phe
 180 185 190
 Asn Leu Arg Val Leu Tyr Ser Tyr Ser Ile Gly Phe Val Tyr Ile Leu
 195 200 205
 Leu Gly Leu Thr Cys Thr Ser Gly Leu Gly Pro Ala Val Thr Phe Cys
 210 215 220
 Ala Lys Asn Pro Val Arg Thr Tyr Gly Tyr Ala Phe Leu Phe Ser Leu
 225 230 235 240
 Thr Gly Tyr Phe Gly Ile Ser Phe Val Leu Ala Leu Ile Lys Ile Phe
 245 250 255
 Gly Ala Leu Ile Ala Val Thr Val Thr Thr Gly Arg Lys Ala Met Thr
 260 265 270
 Ile Val Leu Ser Phe Ile Phe Phe Ala Lys Pro Phe Thr Phe Gln Tyr
 275 280 285
 Val Trp Ser Gly Leu Leu Val Val Leu Gly Ile Phe Leu Asn Val Tyr
 290 295 300
 Ser Lys Asn Met Asp Lys Ile Arg Leu Pro Ser Leu Tyr Asp Leu Ile
 305 310 315 320
 Asn Lys Ser Val Glu Ala Arg Lys Ser Arg Thr Leu Ala Gln Thr Val
 325 330 335

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1078 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

CTTCATCACA GGATCAACAC ATTTCATCTG GGCTTCTTAA ATCTAAATCT TTAAATGAC

```

TAAGTTTTCT TCCTTTTCTC TGTTTTTCCT AATAGTTGGG GCTTATATGA CTCATGTGTG      120
TTTCAATATG GAAATTATTG GAGGGAAAGA AGTGTACCTT CATTCCAGGC CATTATATGGC      180
CTCCATCCAG TATGGCGGAC ATCACGTTTG TGGAGGTGTT CTGATTGATC CACAGTGGGT      240
GCTGACAGCA GCCCACTGCC AATATCGGTT TACCAAAGGC CAGTCTCCCA CTGTGGTTTT      300
AGGCGCACAC TCTCTCTCAA AGAATGAGGC CTCCAAACAA ACACTGGAGA TCAAAAAAAT      360
TATACCATTG TCAAGAGTTA CATCAGATCC TCAATCAAAT GATATCATGC TGGTTAAGCT      420
TCAAACAGCC GCAAAACTCA ATAAACATGT CAAGATGCTC CACATAAGAT CCAAAACCTC      480
TCTTAGATCT GGAACCAAAT GCAAGGTTAC TGGCTGGGGA GCCACCGATC CAGATTCAAT      540
AAGACCTTCT GACACCCTGC GAGAAGTCAC TGTTACTGTC CTAAGTCGAA AACTTTGCAA      600
CAGCCAAAGT TACTACAACG GCGACCCTTT TATCACCAA GACATGGTCT GTGCAGGAGA      660
TGCCAAAGGC CAGAAGGATT CCTGTAAGGG TGAATCAGGG GGCCCTTGA TCTGTAAAGG      720
TGTCTTCCAC GCTATAGTCT CTGGAGGTCA TGAATGTGGT GTTGCCACAA AGCCTGGAAT      780
CTACACCCTG TTAACCAAGA AATACCAGAC TTGGATCAAA AGCAACCTTG TTCCGCCTCA      840
TACAAATTAA GTTACAAATA ATTTTATTGG ATGCACTTGC TTCTTTTTTC CTAATATGCT      900
CGCAGGTTAG AGTTGGGTGT AAGTAAAGCA GAGCACATAT GGGGTCCATT TTTGCACTTG      960
TAAGTCATTT TATTAAGGAA TCAAGTTCTT TTTCACTTGT ATCACTGATG TATTTCTACC     1020
ATGCTGTTTT TATTCTAAAT AAAATTTAGA AGACTCTCAA AAAAAAAAAA AAAAAAAA     1078

```

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 264 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

```

Met Thr Lys Phe Ser Ser Phe Ser Leu Phe Phe Leu Ile Val Gly Ala
1           5           10           15
Tyr Met Thr His Val Cys Phe Asn Met Glu Ile Ile Gly Gly Lys Glu
20          25          30
Val Ser Pro His Ser Arg Pro Phe Met Ala Ser Ile Gln Tyr Gly Gly
35          40          45
His His Val Cys Gly Gly Val Leu Ile Asp Pro Gln Trp Val Leu Thr
50          55          60
Ala Ala His Cys Gln Tyr Arg Phe Thr Lys Gly Gln Ser Pro Thr Val

```

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1686 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

CGATAATCTT	CTTCCATTTT	TGCGGAAATT	TATTGCATCC	TTCTTTAAAC	CGGGGTTTGA	60
GAAGTATAAT	AACTTGGATC	TGTTTCGGTA	TCTCTTAAAT	ATTCACGAGC	CAATTGACAT	120
TCCATCTCGT	TTATGTAAAG	GGAATTTTGA	TGATGATATG	TTTAACCACC	AAGTTCCTTA	180
TTTGTGGCTG	ATTTACTGCC	TTTGTCAATC	TCTTCAATCA	AGTATTAAAG	AAACAGTGGG	240
GGCATATGAG	GCAGCATTAG	GGGTGGCTAT	GAGATGTGAT	ATAGTACAGA	AGATATGGAT	300

```

GGATTATCTT GTCTTTGCAA ATAATAGAGC TGCTGGATCC AGAAACAAAG TTCAAGAATT      360
CAAATTTTTT ACTGATTTAG TGAATAGATG TTTGGTTACA GTCCCTGCCC GATACCCCAT      420
TCCTTTTAGC AGTGTGATT ACTGGTCCAA CTATGAATTT CATAATAGGG TTATTTTCTT      480
TTATTTGAGC TGTGTTCCAA AGACCCAGCA TTCCAAAACC TTGGAACGGT TTTGTTCACT      540
TATGCCAGCT AATTCTGGAC TTGCATTGAG GTTACTTCAA CATGAATGGG AAGAAAGCAA      600
TGTTTCAGATT CTGAACTTC AAGCCAAGAT GTTTACATAT AATATCCCAA CATGCCTGGC      660
CACCTGGAAG ATAGCCATTG CTGCTGAGAT TGTTCTAAAG GGACAAAGAG AGGTCCACCG      720
TTTATATCAG AGAGCCTTAC AGAAGTTACC TCTTTGTGCA TCACTGTGGA AAGATCAACT      780
CTTGTTTGAA GCATCAGAAG GAGGTAAAAC TGATAACCTG AGAAACTAG TTTCCAAGTG      840
CCAAGAGATT GGAGTCAGCC TAAATGAGCT CTTAAATTTA AACAGTAACA AAACAGAAAG      900
CAAGAATCAC TGAACACTGG GTGCAGTCAG TTCTAAGTCC TTATAATAAT TGCCAAAATT      960
ATTTGAATGA TTCTTCAAGA TTAGGCTGAT CCCTGGCTAA GGTCTGTGTA AGGCAGACAA     1020
GCGTTATTGA TCATATCAAG TTCCCTACAA TATCCTGTCC TCAAAACCGG AAGCAATGAA     1080
CATGATCCTC TTCGGTTGGA TAAATGAACT TCCTGTTTGG CCTGCTTCTA GGCCCTGCCA     1140
GATTCTCATA ACATCATATA CGTAAGTATA GTTCCTCAA GTGACTGACA TTTATTTTAA     1200
TTTTGCTTTG TTTTTTTTTA TTTTCTCCCC CATTCCTTTA TTTTGTGTTA TTCCTGACTC     1260
ACTTGACACT CTCTGATGCC TGAGAGATTC CTGTTTGGGA TTTAATATCC AGGGCTGTGT     1320
TTACAGTAAA AAAAGCAGGC AGTCCCTTTT AGTTTTCCT TTTTAAATTT TTTTGAGATT     1380
CTTCATTTC AAGATTTTAAA ACTATAGCAG TCCATCTTAA GGAAAGTGTA ACTGCCATGG     1440
CCACAAGTCT GCTAGTTGCA CTTGAATGCT CTATCAGGGT TGTTTATTAC CCTTTCTACG     1500
TTCTGGACTC CTTGCCGAGA CTGTTTAACT TGAAGATTAA AGAACTATT GCAAATGCCA     1560
GTGCATCAGA ACCTAAGAGT GGTCAAATAT TATGTGCAAT TTTTGTGTA AGAAATTTTA     1620
ATTTATAATA AAGTTTAAAC GTTTAAAGAA CAAAAAAAAA AAAAAAAAAA AAAAAAAAAA     1680
AAAAAA                                           1686

```

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 251 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Met Phe Asn His Gln Val Pro Tyr Leu Trp Leu Ile Tyr Cys Leu Cys
 1 5 10 15
 His Pro Leu Gln Ser Ser Ile Lys Glu Thr Val Glu Ala Tyr Glu Ala
 20 25 30
 Ala Leu Gly Val Ala Met Arg Cys Asp Ile Val Gln Lys Ile Trp Met
 35 40 45
 Asp Tyr Leu Val Phe Ala Asn Asn Arg Ala Ala Gly Ser Arg Asn Lys
 50 55 60
 Val Gln Glu Phe Lys Phe Phe Thr Asp Leu Val Asn Arg Cys Leu Val
 65 70 75 80
 Thr Val Pro Ala Arg Tyr Pro Ile Pro Phe Ser Ser Ala Asp Tyr Trp
 85 90 95
 Ser Asn Tyr Glu Phe His Asn Arg Val Ile Phe Phe Tyr Leu Ser Cys
 100 105 110
 Val Pro Lys Thr Gln His Ser Lys Thr Leu Glu Arg Phe Cys Ser Val
 115 120 125
 Met Pro Ala Asn Ser Gly Leu Ala Leu Arg Leu Leu Gln His Glu Trp
 130 135 140
 Glu Glu Ser Asn Val Gln Ile Leu Lys Leu Gln Ala Lys Met Phe Thr
 145 150 155 160
 Tyr Asn Ile Pro Thr Cys Leu Ala Thr Trp Lys Ile Ala Ile Ala Ala
 165 170 175
 Glu Ile Val Leu Lys Gly Gln Arg Glu Val His Arg Leu Tyr Gln Arg
 180 185 190
 Ala Leu Gln Lys Leu Pro Leu Cys Ala Ser Leu Trp Lys Asp Gln Leu
 195 200 205
 Leu Phe Glu Ala Ser Glu Gly Gly Lys Thr Asp Asn Leu Arg Lys Leu
 210 215 220
 Val Ser Lys Cys Gln Glu Ile Gly Val Ser Leu Asn Glu Leu Leu Asn
 225 230 235 240
 Leu Asn Ser Asn Lys Thr Glu Ser Lys Asn His
 245 250

What is claimed is:

1. A composition comprising an isolated polynucleotide selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:2;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:2 from nucleotide 1 to nucleotide 1014;
 - (c) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone G52_24 deposited under accession number ATCC 98028;
 - (d) a polynucleotide encoding the full length protein encoded by the cDNA insert of clone G52_24 deposited under accession number ATCC 98028;
 - (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone G52_24 deposited under accession number ATCC 98028;
 - (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone G52_24 deposited under accession number ATCC 98028;
 - (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:3;
 - (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:3 having biological activity;
 - (i) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:26 from nucleotide 732 to nucleotide 1274;
 - (j) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:27;
 - (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(d) or (i) above;
 - (l) a polynucleotide which encodes a species homologue of the protein of (g), (h) or (j) above; and
 - (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
2. A composition of claim 1 wherein said polynucleotide is operably linked to an expression control sequence.

3. A host cell transformed with a composition of claim 2.
4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein, which comprises:
 - (a) growing a culture of the host cell of claim 3 in a suitable culture medium; and
 - (b) purifying the protein from the culture
6. A protein produced according to the process of claim 5.
7. The protein of claim 6 comprising a mature protein.
8. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
 - (a) the amino acid sequence of SEQ ID NO:3;
 - (b) the amino acid sequence of SEQ ID NO:3 from amino acid 201 to amino acid 221;
 - (c) fragments of the amino acid sequence of SEQ ID NO:3; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone G52_24 deposited under accession number ATCC98028;
 - (e) the amino acid sequence of SEQ ID NO:27;
 - (f) the amino acid sequence of SEQ ID NO:27 beginning with amino acid 41;the protein being substantially free from other mammalian proteins.
9. The composition of claim 8, wherein said protein comprises the amino acid sequence of SEQ ID NO:3.
10. The composition of claim 8, wherein said protein comprises the amino acid sequence of SEQ ID NO:2 from amino acid 201 to amino acid 221.
11. The composition of claim 8, further comprising a pharmaceutically acceptable carrier.

12. A method for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition of claim 11.

13. The gene corresponding to the cDNA sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:26.

14. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 181 to nucleotide 325;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 274 to nucleotide 325;
- (d) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone M97_2 deposited under accession number ATCC 98028;
- (e) a polynucleotide encoding the full length protein encoded by the cDNA insert of clone M97_2 deposited under accession number ATCC 98028;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone M97_2 deposited under accession number ATCC 98028;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone M97_2 deposited under accession number ATCC 98028;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity;
- (j) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:28 from nucleotide 171 to nucleotide 587;
- (k) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:29;
- (l) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) or (j) above; and

- (m) a polynucleotide which encodes a species homologue of the protein of (h), (i) or (k) above.

15. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:6;
 - (b) the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 48;
 - (c) fragments of the amino acid sequence of SEQ ID NO:6; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone M97_2 deposited under accession number ATCC98028;
 - (e) the amino acid sequence of SEQ ID NO:29;
- the protein being substantially free from other mammalian proteins.

16. The gene corresponding to the cDNA sequence of SEQ ID NO:5, SEQ ID NO:7 or SEQ ID NO:28.

17. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 36 to nucleotide 522;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 93 to nucleotide 522;
- (d) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone H1075_1 deposited under accession number ATCC 98028;
- (e) a polynucleotide encoding the full length protein encoded by the cDNA insert of clone H1075_1 deposited under accession number ATCC 98028;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone H1075_1 deposited under accession number ATCC 98028;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone H1075_1 deposited under accession number ATCC 98028;

- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:9;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:9 having biological activity;
- (j) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:30 from nucleotide 19 to nucleotide 471;
- (k) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:31;
- (l) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) or (j) above; and
- (m) a polynucleotide which encodes a species homologue of the protein of (h), (i) or (k) above .

18. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:9;
- (b) the amino acid sequence of SEQ ID NO:9 from amino acid 1 to amino acid 101;
- (c) fragments of the amino acid sequence of SEQ ID NO:9;
- (d) the amino acid sequence encoded by the cDNA insert of clone H1075_1 deposited under accession number ATCC98028;
- (e) the amino acid sequence of SEQ ID NO:31; and
- (f) the amino acid sequence of SEQ ID NO:31 beginning with amino acid 20;

the protein being substantially free from other mammalian proteins.

19. The gene corresponding to the cDNA sequence of SEQ ID NO:8, SEQ ID NO:10 or SEQ ID NO:30.

20. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 88 to nucleotide 499;

- (c) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone J59_41 deposited under accession number ATCC 98028;
- (d) a polynucleotide encoding the full length protein encoded by the cDNA insert of clone J59_41 deposited under accession number ATCC 98028;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone J59_41 deposited under accession number ATCC 98028;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone J59_41 deposited under accession number ATCC 98028;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity;
- (i) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 62 to nucleotide 1069;
- (j) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:33 beginning with amino acid 185;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) or (i) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (g), (h) or (j) above; and
- (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

21. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
- (b) the amino acid sequence of SEQ ID NO:12 from amino acid 45 to amino acid 113;
- (c) fragments of the amino acid sequence of SEQ ID NO:12;
- (d) the amino acid sequence encoded by the cDNA insert of clone J59_41 deposited under accession number ATCC98028;
- (e) the amino acid sequence of SEQ ID NO:33;

(f) the amino acid sequence of SEQ ID NO:33 beginning with amino acid 185;
the protein being substantially free from other mammalian proteins.

22. The gene corresponding to the cDNA sequence of SEQ ID NO:11 or SEQ ID NO:13 or SEQ ID NO:33.

23. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:14;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:14 from nucleotide 138 to nucleotide 479;
- (c) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone H83_22 deposited under accession number ATCC 98028;
- (d) a polynucleotide encoding the full length protein encoded by the cDNA insert of clone H83_22 deposited under accession number ATCC 98028;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone H83_22 deposited under accession number ATCC 98028;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone H83_22 deposited under accession number ATCC 98028;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:15;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:15 having biological activity;
- (i) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:34 from nucleotide 56 to nucleotide 847;
- (j) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:35;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) or (i) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (g), (h) or (j) above ; and

(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).

24. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:15;
 - (b) fragments of the amino acid sequence of SEQ ID NO:15;
 - (c) the amino acid sequence encoded by the cDNA insert of clone H83_22 deposited under accession number ATCC98028; and
 - (d) the amino acid sequence of SEQ ID NO:35;
- the protein being substantially free from other mammalian proteins.

25. The gene corresponding to the cDNA sequence of SEQ ID NO:14 or SEQ ID NO:16 or SEQ ID NO:34.

26. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 149 to nucleotide 461;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 212 to nucleotide 461;
- (d) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone J143_1 deposited under accession number ATCC 98028;
- (e) a polynucleotide encoding the full length protein encoded by the cDNA insert of clone J143_1 deposited under accession number ATCC 98028;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone J143_1 deposited under accession number ATCC 98028;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone J143_1 deposited under accession number ATCC 98028;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;

- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity;
- (j) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:36 from nucleotide 158 to nucleotide 910;
- (k) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:37;
- (l) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) or (j) above; and
- (m) a polynucleotide which encodes a species homologue of the protein of (h), (i) or (k) above.


27. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:18;
- (b) fragments of the amino acid sequence of SEQ ID NO:18;
- (c) the amino acid sequence encoded by the cDNA insert of clone J143_1 deposited under accession number ATCC98028;
- (d) the amino acid sequence of SEQ ID NO:36; and
- (e) the amino acid sequence of SEQ ID NO:36 beginning with amino acid 22;

the protein being substantially free from other mammalian proteins.

28. The gene corresponding to the cDNA sequence of SEQ ID NO:17 or SEQ ID NO:19 or SEQ ID NO:36.

FIGURE 1A




Plasmid name: pED6dpc2

Plasmid size: 5374 bp

Comments/References: pED6dpc2 is derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning. SST cDNAs are cloned between EcoRI and NotI. pED vectors are described in Kaufman et al.(1991), NAR 19: 4485-4490.

FIGURE 1B



Plasmid name: pNOTs
Plasmid size: 4529 bp

Comments/References: pNOTs is a derivative of pMT2 (Kaufman et al,1989. Mol.Cell.Biol.9:1741-1750). DHFR was deleted and a new polylinker was inserted between EcoRI and HpaI. M13 origin of replication was inserted in the ClaI site. SST cDNAs are cloned between EcoRI and NotI

THIS PAGE BLANK (USPTO)